Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis.
Abbadessa G, Ponzano M, Bile F, Miele G, Signori A, Cepparulo S, Sparaco M, Signoriello E, Maniscalco GT, Lanzillo R, Morra VB, Lus G, Sormani MP, Lavorgna L, Bonavita S. Abbadessa G, et al. Among authors: signori a. Mult Scler Relat Disord. 2023 Jul;75:104731. doi: 10.1016/j.msard.2023.104731. Epub 2023 Apr 28. Mult Scler Relat Disord. 2023. PMID: 37163840
Management of the Medico-Legal Dispute of Healthcare-Related SARS-CoV-2 Infections: Evaluation Criteria and Case Study in a Large University Hospital in Northwest Italy from 2020 to 2021.
Barranco R, Caristo I, Spigno F, Ponzano M, Trevisan A, Signori A, Di Biagio A, Ventura F. Barranco R, et al. Among authors: signori a. Int J Environ Res Public Health. 2022 Dec 14;19(24):16764. doi: 10.3390/ijerph192416764. Int J Environ Res Public Health. 2022. PMID: 36554644 Free PMC article.
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, Giannatempo P, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL. Fornarini G, et al. Among authors: signori a. Minerva Urol Nephrol. 2023 Jun;75(3):308-318. doi: 10.23736/S2724-6051.22.05135-7. Epub 2022 Dec 13. Minerva Urol Nephrol. 2023. PMID: 36511379 Free article. Clinical Trial.
Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination.
Dentone C, Fenoglio D, Ponzano M, Cerchiaro M, Altosole T, Franciotta D, Portunato F, Mikulska M, Taramasso L, Magnasco L, Uras C, Magne F, Ferrera F, Scavone G, Signori A, Vena A, Visconti V, Filaci G, Sette A, Grifoni A, Di Biagio A, Bassetti M. Dentone C, et al. Among authors: signori a. Vaccines (Basel). 2022 Oct 24;10(11):1784. doi: 10.3390/vaccines10111784. Vaccines (Basel). 2022. PMID: 36366293 Free PMC article.
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Procopio G, Chiellino S, Milella M, Catalano F, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: signori a. JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185. JAMA Netw Open. 2023. PMID: 38010650 Free PMC article.
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A, Cremante M, Signori A, Rebuzzi SE, Fornarini G, Giudice GC, Maruzzo M, Procopio G, Sorarù M, Di Napoli M, Fratino L, Santini D, Grillone F, Ballestrin M, Dionese M, Nasso C, Catalano F, Murianni V, Rescigno P, Anpalakhan S, Banna GL, Basso U, Buti S. Damassi A, et al. Among authors: signori a. Clin Genitourin Cancer. 2024 Apr;22(2):126-133.e2. doi: 10.1016/j.clgc.2023.10.001. Epub 2023 Oct 6. Clin Genitourin Cancer. 2024. PMID: 37932204
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Corianò M, Giannarelli D, Scartabellati G, De Giorgi U, Brighi N, Fornarini G, Tommasi C, Giudice GC, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Brunelli M, Signori A, Banna GL, Buti S. Corianò M, et al. Among authors: signori a. Expert Rev Anticancer Ther. 2023 May;23(5):545-554. doi: 10.1080/14737140.2023.2200168. Epub 2023 Apr 10. Expert Rev Anticancer Ther. 2023. PMID: 37017710
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, Buti S, Cattrini C, Fornarini G, Bauckneht M, Greystoke A, Plummer R, Oing C, Rescigno P. Messina C, et al. Among authors: signori a. Eur Urol Oncol. 2024 Apr;7(2):179-188. doi: 10.1016/j.euo.2023.07.013. Epub 2023 Aug 12. Eur Urol Oncol. 2024. PMID: 37574390 Free article. Review.
326 results